PMID- 33689096
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20231213
IS  - 1573-6881 (Electronic)
IS  - 0145-479X (Linking)
VI  - 53
IP  - 2
DP  - 2021 Apr
TI  - PYCR1 promotes bladder cancer by affecting the Akt/Wnt/beta-catenin signaling.
PG  - 247-258
LID - 10.1007/s10863-021-09887-3 [doi]
AB  - Pyrroline-5-carboxylate reductase 1 (PYCR1) plays a significant role in the 
      malignant progression of various cancers. However, the role of PYCR1 in bladder 
      cancer has not been well studied. This study was performed to evaluate the 
      potential relevance of PYCR1 in bladder cancer. Our data revealed that PYCR1 
      expression was increased in bladder cancer tissues, and increased expression of 
      PYCR1 was predictive of decreased survival rates. In bladder cancer cell lines, 
      knockdown of PYCR1 caused significantly retarded cell growth and invasion, while 
      PYCR1 overexpression accelerated cellular proliferation and invasion. Moreover, 
      PYCR1 knockdown decreased levels of phosphorylated Akt, and enhanced activation 
      of Wnt/beta-catenin signaling. Akt inhibition markedly abrogated of PYCR1 
      overexpression-mediated activation of Wnt/beta-catenin signaling. In addition, 
      overexpression of beta-catenin partially reversed PYCR1 knockdown-mediated tumor 
      suppression. Notably, PYCR1 knockdown significantly impeded tumor formation and 
      growth in bladder cancer cells in vivo. In conclusion, these data demonstrate 
      that PYCR1 is highly expressed in bladder cancer and knockdown of PYCR1 exerts a 
      remarkable inhibitory effect on tumor formation via downregulation of 
      Akt/Wnt/beta-catenin signaling. Our study suggests a potential role for PYCR1 in 
      promoting bladder cancer progression and indicates that PYCR1 may be utilized as 
      an attractive and promising anticancer target for treatment of bladder cancer.
FAU - Du, Shuangkuan
AU  - Du S
AD  - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, 710068, 
      China.
FAU - Sui, Yongjie
AU  - Sui Y
AUID- ORCID: 0000-0001-7074-2438
AD  - Department of Physical Examination, Shaanxi Provincial People's Hospital, No.256 
      Youyi West Road, Xi'an, 710068, China. sui_yongjie@163.com.
FAU - Ren, Wei
AU  - Ren W
AD  - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, 710068, 
      China.
FAU - Zhou, Jiancheng
AU  - Zhou J
AD  - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, 710068, 
      China.
FAU - Du, Chun
AU  - Du C
AD  - Department of Urology, Shaanxi Provincial People's Hospital, Xi'an, 710068, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210310
PL  - United States
TA  - J Bioenerg Biomembr
JT  - Journal of bioenergetics and biomembranes
JID - 7701859
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (beta Catenin)
RN  - EC 1.5.1.- (Pyrroline Carboxylate Reductases)
SB  - IM
MH  - Animals
MH  - Female
MH  - Heterografts
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Pyrroline Carboxylate Reductases/*metabolism
MH  - Urinary Bladder Neoplasms/genetics/*metabolism/pathology
MH  - *Wnt Signaling Pathway
MH  - beta Catenin/*metabolism
MH  - delta-1-Pyrroline-5-Carboxylate Reductase
OTO - NOTNLM
OT  - Akt
OT  - Bladder cancer
OT  - PYCR1
OT  - Wnt
OT  - beta-Catenin
EDAT- 2021/03/11 06:00
MHDA- 2022/02/09 06:00
CRDT- 2021/03/10 12:29
PHST- 2020/11/02 00:00 [received]
PHST- 2021/03/01 00:00 [accepted]
PHST- 2021/03/11 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
PHST- 2021/03/10 12:29 [entrez]
AID - 10.1007/s10863-021-09887-3 [pii]
AID - 10.1007/s10863-021-09887-3 [doi]
PST - ppublish
SO  - J Bioenerg Biomembr. 2021 Apr;53(2):247-258. doi: 10.1007/s10863-021-09887-3. 
      Epub 2021 Mar 10.